Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Agamemnon Bakakos, Nikoletta Rovina, Stelios Loukides & Petros Bakakos. (2022) Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences. Expert Opinion on Biological Therapy 22:7, pages 855-870.
Read now
Read now
Zhuo Fu, Yongsheng Xu & Chunquan Cai. (2021) Efficacy and safety of omalizumab in children with moderate-to-severe asthma: a meta-analysis. Journal of Asthma 58:10, pages 1350-1358.
Read now
Read now
Stephanie Chen, Sarowar Golam, Julie Myers, Chris Bly, Harry Smolen & Xiao Xu. (2018) Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Current Medical Research and Opinion 34:12, pages 2075-2088.
Read now
Read now
Jonathan Corren, Abhishek Kavati, Benjamin Ortiz, Ashok Vegesna, Jennifer A. Colby, Kimberly Ruiz & Reynold A. Panettieri$suffix/text()$suffix/text(). (2018) Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials. Current Medical Research and Opinion 34:1, pages 65-80.
Read now
Read now
Zahi Nachef, Amita Krishnan, Terry Mashtare, Tingting Zhuang & M. Jeffery Mador. (2018) Omalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: A network meta-analysis. Journal of Asthma 55:1, pages 89-100.
Read now
Read now
J. Mark FitzGerald, Catherine Lemiere, M. Diane Lougheed, Francine M. Ducharme, Sharon D. Dell, Clare Ramsey, M. Connie L. Yang, Andréanne Côté, Wade Watson, Ron Olivenstein, Anne Van Dam, Cristina Villa-Roel & Roland Grad. (2017) Recognition and management of severe asthma: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 1:4, pages 199-221.
Read now
Read now
Christopher L. Grainge, Steven Maltby, Peter G. Gibson, Peter A. B. Wark & Vanessa M. McDonald. (2016) Targeted therapeutics for severe refractory asthma: monoclonal antibodies. Expert Review of Clinical Pharmacology 9:7, pages 927-941.
Read now
Read now
Alberto Nahon Levy, Antonio J. García a Ruiz, Nuria García-Agua Soler & María Victoria Hidalgo Sanjuan. (2015) Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective. Journal of Asthma 52:2, pages 205-210.
Read now
Read now
Yukiko Iino, Mariko Hara, Masayo Hasegawa, Shingo Matsuzawa, Akihiro Shinnabe, Hiromi Kanazawa & Naohiro Yoshida. (2014) Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media. Acta Oto-Laryngologica 134:4, pages 366-372.
Read now
Read now
Articles from other publishers (34)
V. V. Naumova, E. K. Beltyukov, D. V. Kiseleva, A. A. Shtanova & D. A. Stepina. (2023) Omalizumab: a quarter of a century in the fight against T2-inflammatory diseases of upper and lower respiratory tract. Meditsinskiy sovet = Medical Council:20, pages 68-83.
Crossref
Crossref
Khi Yung Fong, Joseph J. Zhao, Nicholas L. Syn, Parameswaran Nair, Yiong Huak Chan & Pyng Lee. (2023) Comparing bronchial thermoplasty with biologicals for severe asthma: Systematic review and network meta-analysis. Respiratory Medicine 216, pages 107302.
Crossref
Crossref
Tyler Pitre, Tanvir Jassal, Albi Angjeli, Vineeth Jarabana, Sricherry Nannapaneni, Ayesha Umair, Muizz Hussain, Gareth Leung, Sarah Kirsh, Johnny Su, Kairavi Desai, Jade Coyne, Sindu Mohan & Dena Zeraatkar. (2023) A comparison of the effectiveness of biologic therapies for asthma. Annals of Allergy, Asthma & Immunology 130:5, pages 595-606.
Crossref
Crossref
Madelyn H. Miller, Lindsay G. Swaby, Vanessa S. Vailoces, Maggie LaFratta, Yuan Zhang, Xiang Zhu, Dorilyn J. Hitchcock, Travis J. Jewett, Bin Zhang & Justine T. Tigno-Aranjuez. (2023) LMAN1 is a receptor for house dust mite allergens. Cell Reports 42:3, pages 112208.
Crossref
Crossref
William J. Calhoun & Geoffrey L. Chupp. (2022) The new era of add-on asthma treatments: where do we stand?. Allergy, Asthma & Clinical Immunology 18:1.
Crossref
Crossref
Lorenzo Salvati, Francesco Liotta, Francesco Annunziato & Lorenzo Cosmi. (2022) Therapeutical Targets in Allergic Inflammation. Biomedicines 10:11, pages 2874.
Crossref
Crossref
Serafeim Chrysovalantis Kotoulas, Ioanna Tsiouprou, Eva Fouka, Athanasia Pataka, Despoina Papakosta & Konstantinos Porpodis. (2022) Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma. Journal of Personalized Medicine 12:2, pages 165.
Crossref
Crossref
Pablo Ciudad-Gutiérrez, Beatriz Fernández-Rubio & Ana Belén Guisado-Gil. (2021) Gender bias in clinical trials of biological agents for severe asthma: A systematic review. PLOS ONE 16:9, pages e0257765.
Crossref
Crossref
Katrine Prætorius, Daniel P. Henriksen, Johannes M. Schmid, Pernille Printzlau, Lars Pedersen, Hanne Madsen, Ehm A. Andersson, Louise Klokker Madsen & Bo L. Chawes. (2021)
Indirect comparison of efficacy of dupilumab
versus
mepolizumab and omalizumab for severe type 2 asthma
. ERJ Open Research 7:3, pages 00306-2021.
Crossref
Crossref
A. Arrobas, M.P. Barbosa, S. Rabiais, B. Vandewalle & J. Félix. (2021) Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients. Pulmonology 27:2, pages 124-133.
Crossref
Crossref
Daniel P. Henriksen, Uffe Bodtger, Kirsten Sidenius, Niels Maltbaek, Lars Pedersen, Hanne Madsen, Ehm A. Andersson, Ole Norgaard, Louise K. Madsen & Bo L. Chawes. (2020) Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma. Allergy, Asthma & Clinical Immunology 16:1.
Crossref
Crossref
Ioana Agache, Claudio Rocha, Jessica Beltran, Yang Song, Margarita Posso, Ivan Solà, Pablo Alonso‐Coello, Cezmi Akdis, Mubeccel Akdis, Giorgio W. Canonica, Thomas Casale, Tomas Chivato, Jonathan Corren, Stefano Del Giacco, Thomas Eiwegger, Davide Firinu, James E. Gern, Eckard Hamelmann, Nicola Hanania, Mika Mäkelä, Irene Hernández Martín, Parameswaran Nair, Liam O'Mahony, Nikolaos G. Papadopoulos, Alberto Papi, Hae‐Sim Park, Luis Pérez de Llano, Santiago Quirce, Joaquin Sastre, Mohamed Shamji, Jurgen Schwarze, Carlos Canelo‐Aybar, Oscar Palomares & Marek Jutel. (2020) Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma. Allergy 75:5, pages 1043-1057.
Crossref
Crossref
Raffaele Campisi, Claudia Crimi, Rossella Intravaia, Simona Strano, Alberto Noto, Maria Pia Foschino, Giuseppe Valenti, Vittorio Viviano, Corrado Pelaia, Luisa Ricciardi, Nicola Scichilone & Nunzio Crimi. (2020) Adherence to omalizumab: A multicenter "real-world" study. World Allergy Organization Journal 13:2, pages 100103.
Crossref
Crossref
Nicole Akar-Ghibril, Thomas Casale, Adnan Custovic & Wanda Phipatanakul. (2020) Allergic Endotypes and Phenotypes of Asthma. The Journal of Allergy and Clinical Immunology: In Practice 8:2, pages 429-440.
Crossref
Crossref
Wan Yin Winnie Yeung & Hae Sim Park. (2020) Update on the Management of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity. Yonsei Medical Journal 61:1, pages 4.
Crossref
Crossref
Matshediso C. Mokoka, Melissa J. McDonnell, Elaine MacHale, Breda Cushen, Fiona Boland, Sarah Cormican, Christina Doherty, Frank Doyle, Richard W. Costello & Garrett Greene. (2019) Inadequate assessment of adherence to maintenance medication leads to loss of power and increased costs in trials of severe asthma therapy: results from a systematic literature review and modelling study. European Respiratory Journal 53:5, pages 1802161.
Crossref
Crossref
James G. Krings, Mary Clare McGregor, Leonard B. Bacharier & Mario Castro. (2019) Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent. The Journal of Allergy and Clinical Immunology: In Practice 7:5, pages 1379-1392.
Crossref
Crossref
Kjell Larsson, Björn Ställberg, Karin Lisspers, Gunilla Telg, Gunnar Johansson, Marcus Thuresson & Christer Janson. (2018) Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR). Respiratory Research 19:1.
Crossref
Crossref
Irena Krčmová, Jakub Novosad, Eva Malá & Jan Krejsek. (2018) Small, Prospective, Observational, Pilot Study in Patients with Severe Asthma after Discontinuation of Omalizumab Treatment. Clinical Therapeutics 40:11, pages 1942-1953.
Crossref
Crossref
B. Sposato, M. Scalese, M. Milanese, S. Masieri, C. Cavaliere, M. Latorre, N. Scichilone, A. Matucci, A. Vultaggio, A. Ricci, A. Cresti, P. Santus, A. Perrella & P.L. Paggiaro. (2018) Factors reducing omalizumab response in severe asthma. European Journal of Internal Medicine 52, pages 78-85.
Crossref
Crossref
Adel H. Mansur, Sapna Srivastava, Verity Mitchell, Julie Sullivan & Ismail Kasujee. (2017) Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety. Respiratory Medicine 124, pages 36-43.
Crossref
Crossref
Abir Al Said, Breda Cushen & Richard W Costello. (2017) Targeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money. Therapeutic Advances in Chronic Disease 8:2-3, pages 31-45.
Crossref
Crossref
Amit D. Parulekar, Zuzana Diamant & Nicola A. Hanania. (2017) Role of biologics targeting type 2 airway inflammation in asthma. Current Opinion in Pulmonary Medicine 23:1, pages 3-11.
Crossref
Crossref
Steven Maltby, Peter G. Gibson, Heather Powell & Vanessa M. McDonald. (2017) Omalizumab Treatment Response in a Population With Severe Allergic Asthma and Overlapping COPD. Chest 151:1, pages 78-89.
Crossref
Crossref
A. S. Kolbin, L. S. Namazova-Baranova, E. A. Vishneva, M. Y. Frolov, T. L. Galankin, A. A. Alekseeva & E. A. Dobrynina. (2016) A Pharmaco-Economic Analyzis of Treating Severe Uncontrolled Child Asthma with Omalizumab — Actual Russian Clinical Practice Data. Pediatric pharmacology 13:4, pages 345-353.
Crossref
Crossref
María del Carmen Vennera, Antonio Valero, Estefany Uría, Carles Forné & César Picado. (2016) Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain. Clinical Drug Investigation 36:7, pages 567-578.
Crossref
Crossref
A S Kolbin, T L Galankin, M A Proskurin & Y E Balykina. (2015) Pharmacoeconomic analysis of using of tiotropium bromide (Spiriva® Respimat®) as adjunctive therapy in patients with asthma in the Russian Federation. Russian Journal of Allergy 12:5, pages 49-58.
Crossref
Crossref
Marek Lommatzsch & Johann Christian Virchow. (2015) In Reply. Deutsches Ärzteblatt international.
Crossref
Crossref
B. Mühlbauer & G. W. Sybrecht. (2015) Marginal Effect and Little Clinical Relevance. Deutsches Ärzteblatt international.
Crossref
Crossref
Tianwen Lai, Shaobin Wang, Zhiwei Xu, Chao Zhang, Yun Zhao, Yue Hu, Chao Cao, Songmin Ying, Zhihua Chen, Wen Li, Bin Wu & Huahao Shen. (2015) Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Scientific Reports 5:1.
Crossref
Crossref
Andrei Malinovschi, Alain Van Muylem, Sebastien Michiels & Alain Michils. (2014) FeNO as a predictor of asthma control improvement after starting inhaled steroid treatment. Nitric Oxide 40, pages 110-116.
Crossref
Crossref
Rebecca Normansell, Samantha Walker, Stephen J Milan, E. Haydn Walters & Parameswaran Nair. (2014) Omalizumab for asthma in adults and children. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Nathan Hambly & Parameswaran Nair. (2014) Monoclonal antibodies for the treatment of refractory asthma. Current Opinion in Pulmonary Medicine 20:1, pages 87-94.
Crossref
Crossref
Neil C. ThomsonRekha Chaudhuri. (2012) Omalizumab: Clinical Use for the Management of Asthma. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 6, pages CCRPM.S7793.
Crossref
Crossref